Akari Therapeutics CEO Highlights Differentiated ADC Payload Strategy and Path Toward Clinical Development in New CEO Corner
Key Highlights
- ➤AKTX-101 Phase 1 clinical development targeted for mid-2027
- ➤Akari advances AKTX-101 through IND-enabling studies, GMP manufacturing, and Phase 1 planning
- ➤PH1 spliceosome-modulating payload targets RNA splicing, distinct from common ADC payload classes
- ➤Akari pursuing strategic partnerships for PH1 payload and broader ADC platform
- ➤AKTX-102 targets CEACAM5 using Akari’s PH1 payload and novel antibody construct
Expert Statements
Abizer Gaslightwala, President and Chief Executive Officer of Akari Therapeutics
“It was important for us to gauge interest and excitement in our novel payload technology and its application to ADC therapies in areas of growing unmet needs like ADC refractory patients, and I left the conferences even more convicted in our technology, strategy, and execution as a company.”
Abizer Gaslightwala, President and Chief Executive Officer of Akari Therapeutics
“Across recent partner discussions and industry engagement, our novel PH1 payload generated meaningful interest and reinforced our belief that differentiated payloads can play an increasingly important role as ADC therapies continue to evolve.”
Abizer Gaslightwala, President and Chief Executive Officer of Akari Therapeutics
“Our focus now is execution”
Abizer Gaslightwala, President and Chief Executive Officer of Akari Therapeutics
“We are advancing the work required to move AKTX-101 into the clinic while continuing to explore the broader potential of PH1. We believe successful execution could create multiple opportunities for value creation through AKTX-101, potential licensing of our payload technology, and new concepts such as dual-payload approaches based on PH1.”
Abizer Gaslightwala, President and Chief Executive Officer of Akari Therapeutics
“We believe Akari has built a differentiated scientific foundation”
Abizer Gaslightwala, President and Chief Executive Officer of Akari Therapeutics
“The next step is to translate that foundation through disciplined execution and demonstrate the potential of this technology in the clinic.”
CEO Abizer Gaslightwala discusses Akari’s novel PH1 payload strategy and execution priorities supporting AKTX-101’s advancement toward planned Phase 1 clinical development in mid-2027
Recent deal activity and emerging clinical data highlighting limitations of current ADC sequencing reinforce the increasing demand for novel ADC payloads
Get started
Create a free account to read the full story.